Next Article in Journal
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
Next Article in Special Issue
Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice
Previous Article in Journal
Nanoantibiotics Based in Mesoporous Silica Nanoparticles: New Formulations for Bacterial Infection Treatment
Previous Article in Special Issue
Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments
Review

Nanotechnology for Age-Related Macular Degeneration

1
Department of Anesthesiology, The Second Hospital of Jilin University, Changchun 130012, China
2
School of Life Sciences, Jilin University, Changchun 130012, China
*
Author to whom correspondence should be addressed.
Academic Editors: Ron Neumann and Yvonne Perrie
Received: 14 September 2021 / Revised: 4 November 2021 / Accepted: 22 November 2021 / Published: 29 November 2021
(This article belongs to the Special Issue Recent Advances in Retinal Drug Delivery)
Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD. View Full-Text
Keywords: age-related macular degeneration (AMD); nano-drug delivery system; cyclodextrin; CRISPR/Cas9; adeno-associated virus (AAV); hyaluronic acid; non-viral vector age-related macular degeneration (AMD); nano-drug delivery system; cyclodextrin; CRISPR/Cas9; adeno-associated virus (AAV); hyaluronic acid; non-viral vector
Show Figures

Figure 1

MDPI and ACS Style

Yang, B.; Li, G.; Liu, J.; Li, X.; Zhang, S.; Sun, F.; Liu, W. Nanotechnology for Age-Related Macular Degeneration. Pharmaceutics 2021, 13, 2035. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122035

AMA Style

Yang B, Li G, Liu J, Li X, Zhang S, Sun F, Liu W. Nanotechnology for Age-Related Macular Degeneration. Pharmaceutics. 2021; 13(12):2035. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122035

Chicago/Turabian Style

Yang, Bo, Ge Li, Jiaxin Liu, Xiangyu Li, Shixin Zhang, Fengying Sun, and Wenhua Liu. 2021. "Nanotechnology for Age-Related Macular Degeneration" Pharmaceutics 13, no. 12: 2035. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122035

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop